{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:22:54Z","timestamp":1777526574601,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T00:00:00Z","timestamp":1433894400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1480-x","type":"journal-article","created":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T22:01:46Z","timestamp":1433973706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma"],"prefix":"10.1186","volume":"15","author":[{"given":"Roman","family":"Kloeckner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"Prinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pinto dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Ruckes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Dueber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Bernhard","family":"Pitton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,10]]},"reference":[{"issue":"5","key":"1480_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ejca.2011.12.021","volume":"48","author":"European Association for Study of L","year":"2012","unstructured":"European Association for Study of L, European Organisation for R, Treatment of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48(5):599\u2013641.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1480_CR2","first-page":"69","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69\u201390.","journal-title":"CA: a cancer journal for clinicians"},{"issue":"10","key":"1480_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJM199903113401001","volume":"340","author":"HB El-Serag","year":"1999","unstructured":"El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745\u201350.","journal-title":"N Engl J Med"},{"issue":"3","key":"1480_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329\u201338.","journal-title":"Semin Liver Dis"},{"issue":"10","key":"1480_CR5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698\u2013711.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1480_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00270-013-0656-5","volume":"37","author":"I Bargellini","year":"2014","unstructured":"Bargellini I, Florio F, Golfieri R, Grosso M, Lauretti DL, Cioni R. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol. 2014;37(2):438\u201344.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"1480_CR7","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jhep.2012.01.008","volume":"56","author":"M Burrel","year":"2012","unstructured":"Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012;56(6):1330\u20135.","journal-title":"J Hepatol"},{"issue":"1","key":"1480_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","volume":"33","author":"J Lammer","year":"2010","unstructured":"Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41\u201352.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"1480_CR9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/PPO.0b013e3181c5214b","volume":"15","author":"DK Reyes","year":"2009","unstructured":"Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009;15(6):526\u201332.","journal-title":"Cancer J"},{"issue":"11","key":"1480_CR10","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.jvir.2011.07.002","volume":"22","author":"R Sacco","year":"2011","unstructured":"Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22(11):1545\u201352.","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"1480_CR11","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1872-034X.2012.01010.x","volume":"42","author":"H Malenstein van","year":"2012","unstructured":"van Malenstein H, Komuta M, Verslype C, Vandecaveye V, Van Calster B, Topal B, et al. Histology obtained by needle biopsy gives additional information on the prognosis of hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology. 2012;42(10):990\u20138.","journal-title":"Hepatology research : the official journal of the Japan Society of Hepatology"},{"issue":"6","key":"1480_CR12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jso.21522","volume":"101","author":"R Dhanasekaran","year":"2010","unstructured":"Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol. 2010;101(6):476\u201380.","journal-title":"J Surg Oncol"},{"issue":"5","key":"1480_CR13","first-page":"1377","volume":"27","author":"F Recchia","year":"2012","unstructured":"Recchia F, Passalacqua G, Filauri P, Doddi M, Boscarato P, Candeloro G, et al. Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicineluting beads compared with lipiodol. Oncol Rep. 2012;27(5):1377\u201383.","journal-title":"Oncol Rep"},{"issue":"6","key":"1480_CR14","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jhep.2012.07.017","volume":"57","author":"MJ Song","year":"2012","unstructured":"Song MJ, Chun HJ, do Song S, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57(6):1244\u201350.","journal-title":"J Hepatol"},{"key":"1480_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/1756-9966-29-164","volume":"29","author":"M Scartozzi","year":"2010","unstructured":"Scartozzi M, Baroni GS, Faloppi L, Paolo MD, Pierantoni C, Candelari R, et al. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. Journal of experimental & clinical cancer research : CR. 2010;29:164.","journal-title":"Journal of experimental & clinical cancer research : CR"},{"issue":"2","key":"1480_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jvir.2012.10.025","volume":"24","author":"NJ Petruzzi","year":"2013","unstructured":"Petruzzi NJ, Frangos AJ, Fenkel JM, Herrine SK, Hann HW, Rossi S, et al. Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24(2):266\u201373.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"1480_CR17","doi-asserted-by":"publisher","first-page":"CR189","DOI":"10.12659\/MSM.881714","volume":"17","author":"P Wiggermann","year":"2011","unstructured":"Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, et al. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin\/lipiodol (cTACE). Medical science monitor : international medical journal of experimental and clinical research. 2011;17(4):CR189\u201395.","journal-title":"Medical science monitor : international medical journal of experimental and clinical research"},{"issue":"124","key":"1480_CR18","first-page":"813","volume":"60","author":"S Gao","year":"2013","unstructured":"Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepato-Gastroenterology. 2013;60(124):813\u201320.","journal-title":"Hepato-Gastroenterology"},{"issue":"5","key":"1480_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/jgh.12439","volume":"29","author":"K Huang","year":"2014","unstructured":"Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(5):920\u20135.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"1480_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/hep.25950","volume":"57","author":"CY Hsu","year":"2013","unstructured":"Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013;57(1):112\u20139.","journal-title":"Hepatology"},{"issue":"8","key":"1480_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","volume":"60","author":"RNH Pugh","year":"1973","unstructured":"Pugh RNH, Murrayly IM, Dawson JL, Pietroni MC, Williams R. Transection of Esophagus for Bleeding Esophageal Varices. Br J Surg. 1973;60(8):646\u20139.","journal-title":"Br J Surg"},{"issue":"4","key":"1480_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/liv.12307","volume":"34","author":"G Heng-jun","year":"2014","unstructured":"Heng-jun G, Yao-jun Z, Min-shan C, Mei-xian C, Jun-ting H, Li X, et al. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver. 2014;34(4):612\u201320.","journal-title":"Liver international : official journal of the International Association for the Study of the Liver"},{"issue":"5","key":"1480_CR23","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/jhep.2001.23561","volume":"33","author":"S Jonas","year":"2001","unstructured":"Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33(5):1080\u20136.","journal-title":"Hepatology"},{"issue":"1","key":"1480_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archsurg.136.1.25","volume":"136","author":"S Tamura","year":"2001","unstructured":"Tamura S, Kato T, Berho M, Misiakos EP, O\u2019Brien C, Reddy KR, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg. 2001;136(1):25\u201330. discussion 31.","journal-title":"Arch Surg"},{"issue":"12","key":"1480_CR25","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1111\/j.1572-0241.2005.00289.x","volume":"100","author":"C Zavaglia","year":"2005","unstructured":"Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005;100(12):2708\u201316.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1480_CR26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00270-011-0287-7","volume":"35","author":"R Lencioni","year":"2012","unstructured":"Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2012;35(5):980\u20135.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"1480_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"1480_CR28","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1053\/j.gastro.2010.06.035","volume":"139","author":"J Trojan","year":"2010","unstructured":"Trojan J, Zeuzem S. To bead or not to bead: is transarterial chemoembolization with Doxorubicin-eluting beads a new standard of care in hepatocellular carcinoma? Gastroenterology. 2010;139(2):690\u20132.","journal-title":"Gastroenterology"},{"issue":"3","key":"1480_CR29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","volume":"56","author":"B Guiu","year":"2012","unstructured":"Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, et al. Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol. 2012;56(3):609\u201317.","journal-title":"J Hepatol"},{"issue":"9319","key":"1480_CR30","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734\u20139.","journal-title":"Lancet"},{"issue":"5","key":"1480_CR31","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164\u201371.","journal-title":"Hepatology"},{"key":"1480_CR32","first-page":"CD004787","volume":"3","author":"RS Oliveri","year":"2011","unstructured":"Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. The Cochrane database of systematic reviews. 2011;3:CD004787.","journal-title":"The Cochrane database of systematic reviews"},{"issue":"4","key":"1480_CR33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2008.07.012","volume":"49","author":"E Christensen","year":"2008","unstructured":"Christensen E. Choosing the best endpoint. J Hepatol. 2008;49(4):672\u20133.","journal-title":"J Hepatol"},{"issue":"2","key":"1480_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/bjc.2014.199","volume":"111","author":"R Golfieri","year":"2014","unstructured":"Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255\u201364.","journal-title":"Br J Cancer"},{"issue":"1","key":"1480_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","volume":"30","author":"L Marelli","year":"2007","unstructured":"Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30(1):6\u201325.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"1480_CR36","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/00000421-200012000-00006","volume":"23","author":"Y Ono","year":"2000","unstructured":"Ono Y, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K, et al. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol. 2000;23(6):564\u20138.","journal-title":"Am J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1480-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1480-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1480-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1480-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T06:30:39Z","timestamp":1599114639000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1480-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,10]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1480-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,10]]},"article-number":"465"}}